EverSource Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

EverSource Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-259	Closed	-$5.58K	–	4395
2025 Q4	$5.58K	Buy	259 +208	+408%	+$4.04K	﹤0.01%	3086
2025 Q3	$779	Buy	51 +5	+11%	+$65	﹤0.01%	3829
2025 Q2	$407	Buy	46 +19	+70%	+$167	﹤0.01%	3946
2025 Q1	$211	Sell	27 -250	-90%	-$2.09K	﹤0.01%	3695
2024 Q4	$2.91K	Buy	+277	New	+$3.36K	﹤0.01%	2571

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

EverSource Wealth Advisors's AVDL Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 259 shares — an estimated $5.58K sold.

EverSource Wealth Advisors first reported a position in AVDL in Q4 2024 and held it in 5 quarters. The position peaked at $5.58K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

EverSource Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EverSource Wealth Advisors sold 259 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.58K.
EverSource Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 5 quarters.
EverSource Wealth Advisors's Avadel Pharmaceuticals position peaked at $5.58K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.